| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.28 | 1e-05 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.29 | 2e-05 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-05 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.2 | 8e-05 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.22 | 9e-05 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.0001 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.21 | 0.0002 |